drugset
drugset / Trial / NCT06386146

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

NCT06386146 ↗

Phase 1/2 Recruiting 144 enrolled Jacobio Pharmaceuticals Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with advanced solid tumors harboring TP53 Y220C mutation.

Timeline

Start
2024-07-24
Primary completion
2027-01
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject JAB-30355 Unknown — Oral

Indications

cancer